Tokyo, Aug. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058784) titled 'Impact of tirzepatide on FIB-4 in patients with type 2 diabetes' on Aug. 15.
Study Type:
Observational
Primary Sponsor:
Institute - Edogawa Hospital
Condition:
Condition - type 2 diabete
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To observe changes in FIB-4 in patients with type 2 diabetes treated with tirzepatide
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with type 2 diabetes who were administered tirzepatide
Key exclusion criteria - Patients with an observation period of less than 6 months
Target Size - 50
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2024 Year 03 Month 01 Day
Date of IRB - 2025 Year 05 Month 23 Day
Anticipated trial start date - 2024 Year 04 Month 01 Day
Last follow-up date - 2024 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067198
Disclaimer: Curated by HT Syndication.
